Abbott Targets Simcor Filing For First Half 2007
This article was originally published in The Pink Sheet Daily
Executive Summary
Addition of Kos nearly doubles Abbott's 2007 dyslipidemia franchise.
You may also be interested in...
Abbott’s Humira Gets FDA Nod For Adult Plaque Psoriasis
A crowded market for Humira’s fifth indication fails to intimidate Abbott, which envisions the drug as a “formidable competitor” in chronic adult plaque psoriasis, firm tells “The Pink Sheet” DAILY.
Abbott’s Humira Gets FDA Nod For Adult Plaque Psoriasis
A crowded market for Humira’s fifth indication fails to intimidate Abbott, which envisions the drug as a “formidable competitor” in chronic adult plaque psoriasis, firm tells “The Pink Sheet” DAILY.
Abbott Seeks Psoriasis Indication For Humira
The TNF inhibitor would join J&J’s Remicade and Wyeth’s Enbrel with an indication for the treatment of chronic plaque psoriasis.